The EpiVax team wishes you, your colleagues, and family very safe, happy, and healthy holidays! This team is so grateful for our wonderful clients, colleagues, and friends! It has been our privilege working with all of you this year, and we look forward to bigger and better things in 2022.
Catch a glimpse of our fully-vaccinated team below 🙂
Let EpiVax Help You Give Back!
In case you missed it last time: EpiVaxers believe in giving back! In addition to our company and employees’ collective donations of over $100K this year, in the spirit of the holidays, EpiVax wants to help you and your neighborhood!
Do you support a local organization (near you) that champions women in STEM, clean energy, immigrant rights, animal welfare, or neighbors in need? If you do, then send us your donation record before January 7, and EpiVax will match your donations to double your impact in supporting your community. So let us know where you’ve donated!
Help Me Get Back in Touch with You!
Guilty as charged! I write a lot of emails. A LOT! As a result, my email has been black-listed by spam filters! Several collaborators found me in their “junk” files!. Please whitelist my email AnnieD@EpiVax.com so that you don’t miss out on important information!
A Dash of Hope for the Holidays:
Exciting Strides in Oncology
Don’t miss the latest information on Personalized Cancer Vaccines (PCVs) from EpiVax Therapeutics! Learn more about how PCVs are changing the face of cancer therapy. One option: Listen to a great talk recently given by EpiVax Therapeutics’ Lead Computational Immunologist, Guilhem Richard here. Another: read this newly published paper: Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
It describes how…
- The field of cancer therapy has undergone a major transformation due to the advent of next generation sequencing, the introduction of CPIs, and the discovery of neoantigens;
- The realization that a patient’s immune response to their tumor determines their survival; and
- Therefore, cancer vaccine development is undergoing a paradigm shift.
Did you miss this month’s newsletter? Sign-up here